We studied a case series of peripheral nerve hyperexcitability (PNH) aiming to describe clinical characteristics, immunologic and cancer associations, antibodies against neuronal antigens (voltage-gated potassium channel antibodies [VGKC-Abs] and other), and muscle biopsy findings.
Peripheral nerve hyperexcitability (PNH) is a syndrome of spontaneous and continuous muscle fiber activity, cramps, and slow relaxation of muscles of peripheral nerve origin. 1, 2 The electrophysiologic basis consists of spontaneous bursts of single motor unit discharges with a high intraburst frequency. 3 PNH is known to occur secondary to hereditary or acquired diseases affecting the motor neurons and axons. Patients without these diseases are thought to have an axonal hereditary or acquired potassium channelopathy. [4] [5] [6] [7] A group of patients with an idiopathic severe acquired form of this disorder was described by Isaacs 8 and further clinically and immunologically defined by Newsom-Davis. 9 There is an association with autoimmune disorders and cancer. Voltage-gated potassium channel antibodies (VGKC-Abs) are found in 35% of these patients. 2, 10 Of interest, it has recently been suggested that other antigens that interact with the potassium channels might be implicated. 11 Other questions that remain open imply the nosologic limits of Isaacs syndrome. It is not known whether coincident axonal neuropathy in some patients is the cause of PNH, or rather if the putative immune damage against axonal membrane proteins eventually leads to axonal injury. Also, a high proportion of patients have increased serum creatine kinase levels (CK), 2, 9 suggesting muscle damage.
We report our experience in a single tertiary center with a series of patients with PNH. We aimed to study their clinical characteristics, the immunologic and cancer associations, the presence of anti-neuronal antibodies (VGKC-Abs and others), and the pathologic findings in muscle biopsies.
METHODS Patients. We studied all patients attending our neuromuscular clinic with symptoms and signs of PNH (muscle twitching or cramps) involving at least 2 regions of skeletal muscle (cranial, upper limbs, trunk, lower limbs) between 1999 and 2009. All patients had EMG studies showing myokymic (40 -150 Hz) or neuromyotonic (150 -300 Hz) discharges affecting at least 2 regions of skeletal muscle. Patients with hereditary forms of PNH were excluded from further analysis (1 family with Kennedy syndrome, 1 family with spinal distal muscular atrophy, 3 families with hereditary sensory and motor neuropathy). All patients had normal ionograms, calcium, magnesium, and thyroid function and lacked history of toxin exposure. Parental consanguinity was not found. Clinical records were thoroughly reviewed and all living patients were personally reexamined by the authors (I.R.-A., L.B.) before final analysis. Serum and CSF, when lumbar puncture was clinically indicated, were obtained under informed consent and kept frozen at Ϫ80°C until used.
Patients were classified according to the presence or absence of electrophysiologic data of motor axonopathy. Motor axonopathy was defined as 1) decreased amplitude of compound muscle action potentials on nerve conduction studies in multiple bilateral nerves (at least 3 major nerve trunks, 1 of them contralateral to the other 2) or 2) presence on EMG of largeamplitude, long-duration, polyphasic motor units (neuropathic motor units) bilaterally in muscles of multiple regions (see above). 12, 13 Standard protocol approvals, registrations, and patient consents. We received approval from ethical standards institutional committee. Written informed consent for research was obtained from all patients participating in the study.
Immunologic studies. VGKC-Abs assay. An immunoprecipitation assay with 125 I-labeled ␣-dendrotoxin was used, as reported previously. 2 Antibody titers were considered positive if Ͼ100 pM (equivalent to the mean ϩ3 SDs of healthy sera).
Other antineuronal antibodies. Sera of all patients were studied for antineuronal antibodies with indirect immunofluorescence on rat cerebellum and hippocampus. In brief, rats were anesthetized and perfused in 4% paraformaldehyde in phosphate buffered saline (PBS). Then the brain was removed and kept frozen, cerebellum or hippocampus sections obtained, and incubated sequentially with 10% goat serum in PBS with triton-X, the serum of the patients diluted 1:400 in 10% goat serum in PBS-triton-X, and anti-human immunoglobulin G (IgG) (Vector, CA) or immunoglobulin M (IgM) (Vector, CA) labeled with fluorescein.
Systemic antibodies. All patients were tested with standard indirect immunofluorescence on rat tissues for antinuclear antibodies (ANA), striational antibodies, anti-smooth muscle antibodies, anti-mitochondrial antibodies, anti-liver kidney microsomal antibodies, and anti-parietal gastric cell antibodies. According to clinical criteria, some patients were also tested for anti-thyroid, rheumatoid factor, anti-acetylcholine receptor, anti-GM1, anti-SSa/SSb, anti-gliadin, anti-transglutaminase, and Coombs antibodies.
Muscle biopsies.
Ten patients underwent open deltoid muscle biopsy. Six-to eight-micrometer-thick cryostat sections were processed by standard histologic and histochemical methods, including hematoxylin-eosin, modified Gomori trichrome, reduced nicotinamide adenine dinucleotide-tetrazolium reductase, cytochrome C oxidase (COX), succinic dehydrogenase (SDH), and adenosine triphosphatase reactions (ATPase) at pH 4.6 and pH 9.4. Immunohistochemistry procedures were performed by avidin-biotin system (Dako) using the following mouse monoclonal antibodies: dystrophin (NCL-Dys1, NCL-Dys2, and NCL-Dys3, Novocastra), ␣and ␤-sarcoglycan (NCL-a-SARC and NCL-b-SARC, Novocastra), dysferlin (NCL-Hamlet, Novocastra), merosin (Laminin ␣2 chain, Vector Lab), and caveolin (Caveolin 3, Santa Cruz Biotechnology Inc.). Muscle biopsies with inflammatory findings were also studied by immunofluorescence using antibodies against MHC-I, C5b-9 (complement deposition), CD68, and CD8 (Santa Cruz Biotechnology Inc.) as previously reported 14 or immunohistochemistry using anti human-CD4 (Dako).
RESULTS

Classification of patients.
Thirty-eight patients fulfilled the inclusion criteria for our study (see table e-1 on the Neurology ® Web site at www. neurology.org for extended description and numeration). Patients were classified according to the presence or absence of electrophysiologic data of motor axonopathy in 2 groups: axonopathic PNH and isolated PNH (figure 1). After excluding 6 cases with a known cause for the axonopathy (see later), patients were further subdivided into 3 groups: group A (12 patients with PNH and axonopathy of unknown origin); group B (16 patients with isolated PNH not associated with cancer); paraneoplastic PNH (4 patients with isolated PNH associated with cancer).
The 6 patients with a recognizable cause of motor axonopathy included motor neuron disease, multifocal motor neuropathy with conduction block and positive anti-GM1 antibodies, paraproteinemic neuropathy, copper deficiency, diabetes mellitus type 2, and Creutzfeldt-Jakob disease (CJD). All these patients had prominent PNH on clinical examination that led us to consider initially the diagnosis of autoimmune PNH. The patient with CJD presented with subacute cerebellar ataxia, chorea, dementia, and prominent undulating myokymia. He had abnormal hyperintensity of the basal ganglia on MRI and positive 14-3-3 protein in CSF. He died 6 months later and the autopsy study confirmed a prion disease. All patients with axonopathic PNH of known cause proved negative for VGKC-Abs.
Four patients with isolated PNH had a tumor diagnosed within 5 years of the diagnosis of PNH (paraneoplastic PNH). 15 The PNH symptoms improved after tumor treatment. Because of very consistent clinical-immunologic features of these patients (3 patients with myasthenia and thymoma, 1 patient with thyroid carcinoma), they were analyzed separately (paraneoplastic PNH group).
Clinical features. The presenting clinical features are listed in table 1. There was an overlap in the clinical manifestations of groups A and B. They had a similar age at onset, with the mean in the fourth decade. Motor symptoms were very similar in both groups, with cramps and painful spasms being the most common presenting complaint. Muscle hypertrophy was found in 8 patients. No correlation was found between muscle hypertrophy and disease duration ( p ϭ 0.399, Student t for independent samples; p ϭ 0.490, Mann-Whitney U) or raised serum CK ( p ϭ 0.671, Fisher exact test). As expected, patients with axonopathic PNH had weakness, usually mild and distal, and decreased myotatic reflexes more frequently. Only 1 patient with graft vs host disease (GVHD) (patient 17), belonging to group A, showed mild proximal weakness consistent with myopathy. Sensory symptoms consisting mainly of mild distal paresthesiae were frequent in patients with or without overt axonopathy. Hyperhidrosis was present in 6 patients. Other dysautonomic symptoms included sinus tachycardia in 4 patients, 1 of them with associated myocarditis (patient 30), symptomatic postural hypotension in 5, chronic constipation in 2, erectile dysfunction in 3, and incontinence due to detrusor hyperactivity in 1. CNS symptoms such as personality changes, sleep problems, anxiety, and mood changes were common. Three patients with these symptoms underwent brain MRI, which had normal results. However, one of the patients in group B (patient 31) presented also with delirium, temporal seizures, visual hallucinations, subsequent severe anterograde amnesia, and undulating myokymia (limbic encephalitis with PNH). MRI showed FLAIR hyperintensities in both hippocampi characteristic of limbic encephalitis. He had very high titers of VGKC-Abs (Ͼ3,000 pM). One patient in group A (patient 8) had cerebellar ataxia combined with mild motor neuropathy, prominent PNH, and elevated serum CK. Other neurologic symptoms included chronic headache (10 patients), episodic dizziness (6 patients), postural tremor (3 patients), and restless legs syndrome (2 patients).
Patients with paraneoplastic PNH were older (52.5 Ϯ 16.6 SD vs 35 Ϯ 12.7 SD in groups A ϩ B, p ϭ 0.019, Student t for independent samples) and showed a different motor syndrome, with prominent proximal weakness and generalized profuse myokymia, less frequent and less severe cramps, and absent muscle hypertrophy. None of them showed sensory symptoms, hyperhidrosis, or dysautonomic features. Only one patient, with thymoma, showed mild psychiatric symptoms. He had a normal brain MRI.
Immune associations. Associations with clinical autoimmunity and autoantibodies are listed in table e-2. In group B, clinical autoimmunity (thyroiditis, polyarthritis, psoriasis, Coombs-positive hemolytic anemia, other) was present in 63% of patients, and systemic non-neuronal autoantibodies in 75% of patients, suggesting a propensity for autoimmunity. Group A had lower percentages, but still higher than expected by chance. All 3 patients with thymoma had myasthenia gravis, ANA, anti-acetylcholine-receptor antibodies, and high titer striational antibodies.
VGKC-Abs were only detected in 2 patients (patients 25 and 31) in group B, one of them with associated limbic encephalitis. Atypical antineuronal antibodies were detected in 2 patients in group B and one patient with paraneoplastic PNH and thymoma. The patient with axonopathic PNH and IgM monoclonal gammopathy of unknown significance (MGUS) (patient 5) also had atypical IgG and IgM reactivity against neuronal antigens expressed in the cerebellum (figure 2).
Nerve conduction and electromyographic studies. Patients in group A had neurophysiologic studies consistent with axonal motor neuropathy with 3 different patterns: 1) 7 patients had a sensory-motor axonal polyneuropathy. One of these (patient 17), with GVHD, had also myopathic motor unit potentials on EMG of proximal muscles; 2) 4 patients had motor axonopathy as defined by decreased amplitude of the compound motor potential in nerve conduction studies (2 patients) or neuropathic motor units in distal muscles, with a pattern compatible with chronic length-dependent motor axonopathy (2 patients). None of these patients had signs of denervation (positive sharp waves or fibrillation potentials); 3) 1 patient had asymmetric multineuropathy, affecting both sensory and motor nerves. Although all patients in group B had normal electrophysiologic studies at onset, apart from PNH, the patient with limbic encephalitis and PNH (patient 31) developed over months clinical and electrophysiologic signs of motor distal axonopathy, without other evident cause different from VGKC-Abs. Severe hyperexcitability in the form of afterdischarges or neuromyotonic discharges were present in 42% of patients in group A and 25% in group B. They were particularly prevalent in the paraneoplastic group: all patients showed neuromyotonic discharges, and 3 out of 4 had afterdischarges in multiple nerves.
CK and muscle histology. Overall CK levels were raised in 14 patients (38%). Increased CK was very common in group A (58%), usually in a range of 200 -1,000 IU/L, with only 1 patient with Ͼ1,000 IU/L. By contrast, only 4 patients in group B (25%) had raised CK, 2 of them with levels Ͼ1,000 IU/L. Increased CK levels were detected in 3 patients with axonopathic PNH of known cause: motor neuron disease, copper deficiency neuropathy, and paraproteinemic sensory-motor neuropathy. This latter patient had CK in a range of 1,000 -1,500 IU/L. Muscle biopsies were performed in 10 patients. The pathologic findings are summarized in table e-3.
Two biopsies showed findings consistent with an inflammatory myopathy, with predominant endomysial (patient 5, with paraproteinemic neuropathy) or perimysial (patient 17, with GVHD) pathology. Both patients had abnormal sarcolemmal expression of MHC-I antigen in muscle fibers (figure 2), deposits of C5b-9 surrounding vessels, and infiltrates of inflammatory CD8, CD4, and CD68 cells. All the rest had mild nonspecific myopathic changes including abnormally increased variation in muscle fiber size and shape, an increase of internal nuclei, endomysial fibrosis, and mild mitochondrial proliferation on SDH reactions (neither COX-negative fibers nor ragged-red fibers on modified Gomori trichrome were seen) (figure 2). In 2 patients with axonopathic PNH, myopathic changes were mixed with signs of denervation including angulated fiber atrophy, nuclear clumps, and fiber type grouping. Immunohistochemical studies showed normal immunoreactivity for sarcoglycans, dystrophin, dysferlin, merosin, and caveolin. DISCUSSION We found that PNH is a heterogeneous condition arising from peripheral nerve dysfunction in patients with a high propensity for developing autoimmunity. However, the main neuronal or axonal antigen of most patients remained unknown. An unexpected high prevalence of associated muscle disease was found, including raised CK, myositis, nonspecific myopathic pathologic changes, or myasthenia gravis. Prominent PNH was noticed in patients with diseases affecting the motor neurons and axons, such as inherited neuropathies, motor neuron diseases, metabolic derangements, paraproteinemia, and CJD. CJD may rarely present with PNH associated or not with amyotrophy due to loss of motor neurons in ventral horns of the spinal cord. 16 Because there is a wellknown clinical and neuroradiologic overlap between prion disorders and limbic encephalitis associated with VGKC-Abs, 17 it should be noted that the presence of PNH does not distinguish these disorders.
Once known causes of secondary motor axonopathy were ruled out, we found a clinical and immune overlap between patients with isolated and axonopathic PNH. Interestingly, we have observed one patient with high VGKC-Ab titers, limbic encephalitis, and PNH without evidence of neuropathy at onset who eventually developed a subacute motor axonopathy. This suggests that autoimmunity against axonal antigens such as the VGKC initially inducing isolated PNH may finally cause structural axonal degeneration. Taken together, these findings are important because in patients with PNH the presence of an axonal motor neuropathy does not necessarily exclude an underlying autoimmune neuromuscular disease against axonal antigens such as VGKC or other (see below). Such antigens could also be implicated in subacute motor neuron syndromes of unknown origin.
In contrast with previous studies, we found a very low prevalence of VGKC-Abs in our series, with an overall frequency of 5%. There is no clear explanation for this discrepancy. Previous studies found a prevalence of 35%-54%. 2, 10 In the study with the highest prevalence, 10 patient selection criteria were not defined and the cutoff value for the VGKC-Ab assay was lower than ours; therefore, it is possible that there was an overrepresentation of VGKC-Abpositive patients. The percentage of positives is higher when patients with axonopathic PNH are excluded (13% of patients with isolated PNH in the present study, 51%-54% in previous reports 2,10 ). Although VGKC-Ab can be found in patients with PNH when axonal damage is present, it appears that patients with axonopathy are less likely to have an autoimmune basis. Axonopathic PNH groups probably include patients who have disorders that are not autoimmune, but are phenotypically indistinguishable from autoimmune PNH. A clearer clinical, EMG, and immunologic classification of patients with PNH will permit future comparison among different studies.
Although in our study we measured VGKC-Abs, there is now evidence that these antibodies are mainly directed toward other proteins that are present in the VGKC complexes extracted from brain tissue that are used for the immunoprecipitation assay. Antibodies against the VGKC-interacting protein, Caspr2, were identified in some patients with Morvan syndrome, limbic encephalitis, or PNH. 11, [18] [19] [20] However, these tests have not yet been reported in patients with PNH and low or negative VGKC-Ab levels.
Because ours and previous studies have found elevated serum CK in a high proportion of patients with PNH, 2,5 we conducted muscle biopsies and found 2 different patterns. Two patients showed an inflammatory myopathy. Although both had an axonal neuropathy in the context of autoimmune disease (MGUS and GVHD), which could explain PNH, the abnormal discharges may also have originated from the motor nerve terminals close to inflammatory infiltrates surrounding necrotic muscle fibers. 21 Indeed motor nerve terminals are thought to be the origin of the abnormal discharges in most patients with PNH. 22, 23 Autoimmune phenomena affecting the intramuscular arborization of motor nerve terminals may extend to nearby muscular antigens, as it is characteristic of patients with thymoma, PNH, and myasthenia gravis. 24, 25 All other biopsied patients showed nonspecific myopathic changes, including mild signs of mitochondrial proliferation. Further investigations are needed to understand these findings.
